05-361
Anti-NFκB p52 Antibody
Upstate®, from mouse
Synonym(s):
DNA-binding factor KBF2, Lymphocyte translocation chromosome 10, Oncogene Lyt-10, nuclear factor of kappa light chain gene enhancer in B-cells 2, nuclear factor of kappa light polypeptide gene enhancer in B-cells 2, nuclear factor of kappa light polypept
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
12352203
eCl@ss:
32160702
NACRES:
NA.41
Recommended Products
biological source
mouse
Quality Level
antibody form
purified antibody
antibody product type
primary antibodies
clone
monoclonal
species reactivity
human
manufacturer/tradename
Upstate®
technique(s)
electrophoretic mobility shift assay: suitable
immunoprecipitation (IP): suitable
western blot: suitable
isotype
IgG2a
NCBI accession no.
UniProt accession no.
shipped in
dry ice
target post-translational modification
unmodified
General description
The NFκB transcription factor was originally identified as a protein complex consisting of a DNA binding subunit and an associated protein. The DNA binding subunit is functionally related to c-Rel p75 and Rel B p68. The p50 subunit was initially believed to be a functionally unique protein derived from the amino terminus of a precursor designated p105. A cDNA has been isolated that encodes an alternative DNA binding subunit of NFκB. It is synthesized as a protein that is expressed in a variety of cell types and, like p105, undergoes cleavage to generate its NFκB subunit, in this case a protein designated p52 (previously referred to as p49). In contrast to p50 derived from p105, p52 acts in synergy with p65 to stimulate the HIV enhancer in transiently transfected Jurkat cells.
Specificity
Does not cross-react with mouse or rat; other species cross-reactivity is unknown.
This antibody recognizes the p52 subunit of NFκB and its p100 precursor.
Immunogen
GST-fusion protein corresponding to amino acids 1-444 of human NFκB p52 subunit (Schmidt, R., 1991;Bours, V., 1992).
Application
Anti-NFκB p52 Antibody is a Mouse Monoclonal Antibody for detection of NFκB p52 also known as DNA-binding factor KBF2, Lymphocyte translocation chromosome 10, Oncogene Lyt-10 & has been validated in EMSA, IP & WB.
Immunoprecipitation:
4 µg of a previous lot immunoprecipitated NFκB p52 and its p100 precursor from 500 µg of HeLa nuclear extract cell lysate.
Gel Shift Assay:
A previous lot of this antibody used 2 µg per gel shift assay (Bours, V., 1993).
4 µg of a previous lot immunoprecipitated NFκB p52 and its p100 precursor from 500 µg of HeLa nuclear extract cell lysate.
Gel Shift Assay:
A previous lot of this antibody used 2 µg per gel shift assay (Bours, V., 1993).
Research Category
Epigenetics & Nuclear Function
Epigenetics & Nuclear Function
Research Sub Category
Transcription Factors
Transcription Factors
Quality
Routinely evaluated by immunoblotting in HeLa nuclear extract or in human Raji cell, but not in mouse 3T3/A31 cell and rat PC 12 cell lysates
Western Blot Analysis:
0.5-2 µg/mL of this lot detected NFκB p52 and its p100 precursor in HeLa nuclear extract. A previous lot detected NFκB p52 and its p100 precursor in human Raji cell, but not in mouse 3T3/A31 cell and rat PC 12 cell lysates. Highly recommended for western blotting.
Western Blot Analysis:
0.5-2 µg/mL of this lot detected NFκB p52 and its p100 precursor in HeLa nuclear extract. A previous lot detected NFκB p52 and its p100 precursor in human Raji cell, but not in mouse 3T3/A31 cell and rat PC 12 cell lysates. Highly recommended for western blotting.
Target description
52 kDa; precursor at 100 kDa
Physical form
Format: Purified
Protein G Chromatography
Purified mouse monoclonal IgG2a in buffer containing 0.1 M Tris-glycine, pH 7.4, 0.15 M NaCl, 0.05% sodium azide.
Storage and Stability
Stable for 1 year at -20°C from date of receipt.
Handling Recommendations:
Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Handling Recommendations:
Upon receipt, and prior to removing the cap, centrifuge the vial and gently mix the solution. Aliquot into microcentrifuge tubes and store at -20°C. Avoid repeated freeze/thaw cycles, which may damage IgG and affect product performance.
Analysis Note
Control
Positive Antigen Control: Catalog #12-303, Jurkat cell lysate.
Positive Antigen Control: Catalog #12-303, Jurkat cell lysate.
Other Notes
Concentration: Please refer to the Certificate of Analysis for the lot-specific concentration.
Legal Information
UPSTATE is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Unless otherwise stated in our catalog or other company documentation accompanying the product(s), our products are intended for research use only and are not to be used for any other purpose, which includes but is not limited to, unauthorized commercial uses, in vitro diagnostic uses, ex vivo or in vivo therapeutic uses or any type of consumption or application to humans or animals.
Not finding the right product?
Try our Product Selector Tool.
recommended
Product No.
Description
Pricing
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 1
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK.
Carmona Arana, JA; Seher, A; Neumann, M; Lang, I; Siegmund, D; Wajant, H
Frontiers in Immunology null
Antianoikis effect of nuclear factor-kappaB through up-regulated expression of osteoprotegerin, BCL-2, and IAP-1.
Toruner, M; Fernandez-Zapico, M; Sha, JJ; Pham, L; Urrutia, R; Egan, LJ
The Journal of Biological Chemistry null
CD28 delivers a unique signal leading to the selective recruitment of RelA and p52 NF-kappaB subunits on IL-8 and Bcl-xL gene promoters.
Marinari, B; Costanzo, A; Marzano, V; Piccolella, E; Tuosto, L
Proceedings of the National Academy of Sciences of the USA null
Mary Pulvino et al.
Blood, 120(8), 1668-1677 (2012-07-14)
Diffuse large B-cell lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, remains a partially curable disease. Genetic alterations affecting components of NF-κB signaling pathways occur frequently in DLBCL. Almost all activated B cell-like (ABC) DLBCL, which is the least
Alternative splicing variants of IkappaB beta establish differential NF-kappaB signal responsiveness in human cells
Hirano, F., et al
Molecular and cellular biology, 18, 2596-2607 (1998)
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service